查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1450297

气雾疗法市场：现况分析与预测（2023-2030）

Aerosol Treatment Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

气雾疗法用于治疗多种病因，包括慢性呼吸道疾病，如肺炎、慢性阻塞性肺病 (COPD) 和气喘。根据美国疾病管制与预防中心 (CDC) 的数据：在全球范围内，慢性阻塞性肺病、气喘和肺炎等慢性呼吸道疾病的盛行率不断上升，预计将推动气雾剂治疗市场的成长。

根据产品类型，市场分为干粉吸入器、定量吸入器和雾化器。2022年，定量吸入器占了很大的市场。定量吸入器（MDI）提供了一种方便有效的方式将药物直接输送到肺部，长期以来一直是呼吸医学领域的主要产品。MDI 的持续流行和采用背后有多种驱动力。首先，它结构紧凑、便于携带，对于需要频繁吸入或移动吸入的患者来说非常方便。这种移动性使您无论身在何处都可以保持用药习惯，并促进对治疗计划的遵守。其次，计量吸入器可以达到准确且一致的剂量，确保患者每次吸入时都能收到规定量的药物。这种精确度对于管理呼吸系统疾病和实现最佳治疗结果至关重要。

根据分销管道，市场分为医院药房、零售药房、诊所等。零售药局领域在 2022 年占据最大的收入占有率，预计在预测期内将继续占据主导地位。零售药房受到多种因素的推动，这些因素有助于其在市场上的成功和成长。首先，对医疗保健服务和药品的需求不断增长是主要驱动力。随着人口持续增长和老化，对易于取得和方便找到的处方药和非处方药的需求日益增长。零售药局透过提供各种药物和保健产品来满足这一需求，使个人可以轻鬆地在家中或工作场所附近获得所需的药物。

全球气雾疗法市场从地理上分为五个主要区域：北美、拉丁美洲、欧洲、亚太地区以及中东和非洲。由于慢性呼吸道疾病的高盛行率，预计北美将成为最有利可图的气雾治疗市场。由于采用率高，预计欧洲将成为第二个利润最高的气雾疗法市场。

由于经济快速成长，亚太地区是一个不断成长的气雾疗法市场，其中包括人口众多且呼吸道疾病发病率不断上升的中国和印度。由于气雾剂治疗呼吸道疾病的采用率较低，拉丁美洲和中东和非洲地区是气雾剂治疗市场利润最低的地区。

市场多元化，全球和区域市场参与者众多。

目录

第一章 市场介绍

  • 市场定义
  • 主要目标
  • 利益相关者
  • 限制

第二章 研究方法或前提条件

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对气雾剂治疗市场的影响

第六章气雾剂治疗市场收入，2020-2028

第 7 章市场洞察：依产品类型

  • 定量吸入器 (MDI)
  • 干粉吸入器 (DPI)
  • 喷雾器

第 8 章市场洞察：依分销管道

  • 医院药房
  • 零售药店
  • 诊所
  • 其他

第9章市场洞察：依地区

  • 北美
    • 美国
    • 加拿大
    • 其他北美
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 亚太其他地区
  • 世界其他地区

第10章气雾剂治疗市场动态

  • 市场驱动力
  • 市场课题
  • 影响分析

第十一章气雾剂治疗市场机会

第十二章气雾治疗市场趋势

第十三章需求面与供给面分析

  • 需求面分析
  • 供给侧分析

第十四章价值链分析

第15章 竞争场景

  • 竞争格局
    • 波特五力分析

第十六章公司简介

  • Cipla Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vidal Vademecum Spain
  • Arab Drug Company
  • Socopharm Pharmaceuticals S.A.E
  • Takeda Pharmaceutical Company Limited
  • Covis Pharma GmbH
  • Hycomed
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

第十七章 免责声明

简介目录
Product Code: UMHE212631

Aerosol Treatment - Aerosol is a system in which colloid ally present small solid or liquid particles are suspended in another gas. Medication is given out using aerosol in the form of mist droplets. Following inhalation, medication droplets travel from the mouth through the bronchi and alveoli. Aerosol therapy is one of the most efficient ways to treat respiratory problems because it distributes medication directly into the lower airways.

Aerosol therapy is used to treat a variety of causes, including chronic respiratory disorders like pneumonia and chronic obstructive pulmonary disease (COPD) and asthma. In accordance with the Centers for Disease Control and Prevention (CDC). Globally, the increasing prevalence of chronic respiratory conditions such as COPD, asthma, and pneumonia are expected to propel the growth of the aerosol treatment market.

Based on the product type, the market is segmented dry power inhalers, metered dose inhalers, nebulizers. The metered dose inhalers held a significant share of the market in 2022. Metered Dose Inhalers (MDIs) have long been a staple in the field of respiratory medicine, offering a convenient and effective way to deliver medication directly into the lungs. Several driving factors contribute to the continued popularity and widespread use of MDIs. Firstly, their compact and portable nature makes them incredibly convenient for patients who require frequent or on-the-go inhalations. This mobility allows individuals to maintain their medication routine regardless of their location, promoting better adherence to treatment plans. Secondly, MDIs offer precise and consistent dosing, ensuring that patients receive the prescribed amount of medication with each inhalation. This accuracy is vital in managing respiratory conditions and achieving optimal therapeutic outcomes.

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, clinics, and others. The Retail Pharmacies segment accounted for the largest revenue share in 2022 and is also anticipated to continue its dominance during the forecast period. Retail pharmacies are driven by several factors that contribute to their success and growth in the market. Firstly, the increasing demand for healthcare services and medications is a significant driving force. As the population continues to grow and age, the need for accessible and convenient sources of prescription drugs and over-the-counter medications rises. Retail pharmacies fulfill this need by providing a wide range of medicines and healthcare products, making it easy for individuals to access essential medications close to their homes or workplaces.

The global aerosol treatment market is divided into 5 primary geographic regions based on geography: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Due to the high prevalence of chronic respiratory diseases, North America is anticipated to be the most lucrative aerosol therapy market. Due to greater adoption rates, Europe is anticipated to be the second-most lucrative aerosol treatment market.

Because of its burgeoning economies, including China and India, which have large populations and rising rates of respiratory illnesses, Asia Pacific is a growing market for aerosol treatment. Due to the low adoption of aerosols for the treatment of respiratory disorders, Latin America and MEA are the aerosol treatment markets with the lowest profitability.

Some of the major players operating in the market include Cipla, Teva, Vidal Vademecum Spain, Arab Drug Company, Socopharm Laboratory, Takeda, Covis Pharma, Hycomed, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd. The market is diversified with a large number of global and regional market players.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Aerosol Treatment MARKET
  • 2.2.Research Methodology of the Aerosol Treatment MARKET
  • 2.3.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE Aerosol Treatment MARKET

6. Aerosol Treatment MARKET REVENUE (USD BN), 2020-2028F

7. MARKET INSIGHTS BY PRODUCT TYPE

  • 7.1.Metered Dose Inhalers (MDIs)
  • 7.2.Dry Powder Inhalers (DPIs)
  • 7.3.Nebulizers

8. MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 8.1.Hospital Pharmacies
  • 8.2.Retail Pharmacies
  • 8.3.Clinics
  • 8.4.Others

9. MARKET INSIGHTS BY REGION

  • 9.1.North America
    • 9.1.1.U.S.
    • 9.1.2.Canada
    • 9.1.3.Rest of North America
  • 9.2.Europe
    • 9.2.1.Germany
    • 9.2.2.U.K.
    • 9.2.3.France
    • 9.2.4.Italy
    • 9.2.5.Spain
    • 9.2.6.Rest of Europe
  • 9.3.Asia-Pacific
    • 9.3.1.China
    • 9.3.2.Japan
    • 9.3.3.India
    • 9.3.4.Australia
    • 9.3.5.Rest of Asia-Pacific
  • 9.4.Rest of World

10. AEROSOL TREATMENT MARKET DYNAMICS

  • 10.1.Market Drivers
  • 10.2.Market Challenges
  • 10.3.Impact Analysis

11. AEROSOL TREATMENT MARKET OPPORTUNITIES

12. AEROSOL TREATMENT MARKET TRENDS

13. DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1.Demand Side Analysis
  • 13.2.Supply Side Analysis

14. VALUE CHAIN ANALYSIS

15. COMPETITIVE SCENARIO

  • 15.1.Competitive Landscape
    • 15.1.1.Porters Fiver Forces Analysis

16. COMPANY PROFILED

  • 16.1.Cipla Inc.
  • 16.2.Teva Pharmaceutical Industries Ltd.
  • 16.3.Vidal Vademecum Spain
  • 16.4.Arab Drug Company
  • 16.5.Socopharm Pharmaceuticals S.A.E
  • 16.6.Takeda Pharmaceutical Company Limited
  • 16.7.Covis Pharma GmbH
  • 16.8.Hycomed
  • 16.9.Sun Pharmaceutical Industries Ltd.
  • 16.10.Aurobindo Pharma Ltd.

17. DISCLAIMER